Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares 1 3 Year Treasury Bond ETF (SHY) vs 10X Genomics Inc (TXG) Price & Performance

iShares 1 3 Year Treasury Bond ETFTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

iShares 1 3 Year Treasury Bond ETF vs 10X Genomics Inc — how do they compare? iShares 1 3 Year Treasury Bond ETF trades at $81.95, while 10X Genomics Inc trades at $57.68 (market cap $7.61B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

SHYTXG
Sector
Fixed IncomeHealth
52-Week High
$83.18$58.57
52-Week Low
$81.77$11.34
Market Cap
$7.61B
Enterprise Value
$7.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares 1 3 Year Treasury Bond ETF

SHY, the iShares 1-3 Year Treasury Bond ETF, trades at $81.955, up 0.12% on the day, with a bearish technical signal driven by moving averages. Recent news highlights institutional accumulation, including Barry Investment Advisors increasing its stake by 48.1% in Q2 2026 (SEC filing, August 10, 2026), amid fluctuating Treasury yields influenced by inflation data and Middle East tensions. The ETF maintains a steady dividend schedule, with recent payouts of $0.24-$0.25 per share.

Outlook remains cautious due to interest rate uncertainty and inflation pressures, offering income stability but limited growth. Risks include Fed policy shifts and oil-price volatility, while institutional buying signals defensive positioning. The neutral oscillator reading suggests short-term consolidation near current levels.

10X Genomics Inc

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.

Returns comparison

Trailing returns across standard periods

About iShares 1 3 Year Treasury Bond ETF

SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.

Read more on SHY

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG